Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of treatments for neurological and psychiatric disorders. The company's research platform is built on genetic analysis and ion channel biology, targeting specific genetic mutations associated with human diseases. Its lead investigational candidate, azetukalner, is a Kv7 potassium channel opener currently in Phase 3 clinical trials for focal onset seizures, primary generalized tonic-clonic seizures, and major depressive disorder. Xenon is also advancing early-stage programs targeting sodium and potassium channels, including Nav1.7 inhibitors for pain management. Headquartered in Burnaby, British Columbia, the company translates genetic insights into targeted therapies to address significant unmet medical needs.
